Literature DB >> 27585216

Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation.

Bo Y Chun1, Joseph F Rizzo.   

Abstract

PURPOSE OF REVIEW: Review recent advances in clinical and experimental studies of dominant optic atrophy (DOA) to better understand the complexities of pathophysiology caused by the optic atrophy 1 (OPA1) mutation. RECENT
FINDINGS: DOA is the most commonly diagnosed inherited optic atrophy, causing progressive bilateral visual loss that begins early in life. During the past 25 years, there has been substantial progress in the understanding of the clinical, genetic, and pathophysiological basis of this disease. The histopathological hallmark of DOA is the primary degeneration of retinal ganglion cells, preferentially in the papillomacular bundle, which results temporal optic disc pallor and cecocentral scotomata in patients with DOA. Loss of OPA1 protein function by OPA1 gene mutations causes mitochondrial dysfunction because of the loss of mitochondrial fusion, impaired mitochondrial oxidative phosphorylation, increases in reactive oxygen species, and altered calcium homeostasis. These factors lead to apoptosis of retinal ganglion cells by a haploinsufficiency mechanism.
SUMMARY: Improved understanding of the pathophysiology of DOA provides insights that can be used to develop therapeutic approaches to the DOA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27585216     DOI: 10.1097/ICU.0000000000000314

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  18 in total

Review 1.  Mitochondrial dynamics and their potential as a therapeutic target.

Authors:  B N Whitley; E A Engelhart; S Hoppins
Journal:  Mitochondrion       Date:  2019-06-19       Impact factor: 4.160

2.  Whole Exome Sequencing Identifies Two Novel Mutations in the Reticulon 4-Interacting Protein 1 Gene in a Chinese Family with Autosomal Recessive Optic Neuropathies.

Authors:  Xiao-Huan Zou; Xin-Xin Guo; Hui-Zhen Su; Chong Wang; En-Lin Dong; Ning Wang; Wan-Jin Chen; Qi-Jie Zhang
Journal:  J Mol Neurosci       Date:  2019-05-10       Impact factor: 3.444

3.  Mutations in VPS13D lead to a new recessive ataxia with spasticity and mitochondrial defects.

Authors:  Eunju Seong; Ryan Insolera; Marija Dulovic; Erik-Jan Kamsteeg; Joanne Trinh; Norbert Brüggemann; Erin Sandford; Sheng Li; Ayse Bilge Ozel; Jun Z Li; Tamison Jewett; Anneke J A Kievit; Alexander Münchau; Vikram Shakkottai; Christine Klein; Catherine A Collins; Katja Lohmann; Bart P van de Warrenburg; Margit Burmeister
Journal:  Ann Neurol       Date:  2018-06-30       Impact factor: 10.422

Review 4.  3D engineering for optic neuropathy treatment.

Authors:  Wenjing Xuan; Aji Alex Moothedathu; Tuo Meng; David C Gibson; Jinhua Zheng; Qingguo Xu
Journal:  Drug Discov Today       Date:  2020-10-07       Impact factor: 7.851

5.  Comparison of the clinical and genetic features of autosomal dominant optic atrophy and normal tension glaucoma in young Chinese adults.

Authors:  Guohong Tian; Yuhong Chen; Youjia Zhang; Xinghuai Sun
Journal:  Eye (Lond)       Date:  2022-03-10       Impact factor: 3.775

Review 6.  Mitofusin 2: from functions to disease.

Authors:  Riccardo Filadi; Diana Pendin; Paola Pizzo
Journal:  Cell Death Dis       Date:  2018-02-28       Impact factor: 8.469

Review 7.  Manual Acupuncture for Optic Atrophy: A Systematic Review and Meta-Analysis.

Authors:  Fang-Yuan Zhi; Jie Liu; Xiao-Peng Ma; Jue Hong; Ji Zhang; Dan Zhang; Yue Zhao; Li-Jie Wu; Yan-Ting Yang; Dan-Yan Wu; Chen Xie; Ling-Xiang Wu; Cui-Hong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-01       Impact factor: 2.629

8.  An evaluation of genetic causes and environmental risks for bilateral optic atrophy.

Authors:  Andrew T Chen; Lauren Brady; Dennis E Bulman; Arun N E Sundaram; Amadeo R Rodriguez; Edward Margolin; John S Waye; Mark A Tarnopolsky
Journal:  PLoS One       Date:  2019-11-25       Impact factor: 3.240

9.  A ROD-CONE DYSTROPHY IS SYSTEMATICALLY ASSOCIATED TO THE RTN4IP1 RECESSIVE OPTIC ATROPHY.

Authors:  Isabelle Meunier; Béatrice Bocquet; Majida Charif; Claire-Marie Dhaenens; Gael Manes; Patrizia Amati-Bonneau; Agathe Roubertie; Xavier Zanlonghi; Guy Lenaers
Journal:  Retina       Date:  2021-08-01       Impact factor: 3.975

Review 10.  Pluripotent Stem Cell-Based Approaches to Explore and Treat Optic Neuropathies.

Authors:  Oriane Rabesandratana; Olivier Goureau; Gaël Orieux
Journal:  Front Neurosci       Date:  2018-09-20       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.